drugset / Trial / NCT04869761
Stem Cell Therapy for Chronic Kidney Disease
Non-randomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to assess the safety and tolerability of allogeneic mesenchymal stem / stromal cell therapy in individuals with chronic kidney disease.
Timeline
- Start
- 2021-10-07
- Primary completion
- 2023-04-26
- Completion
- 2023-04-26
Publications
- Patel HA, Wang J, Zinn CJ, Learmonth M, Lerman LO, Wolfram J, Hickson LJ. Fortifying the Diabetic Kidney Disease Treatment Armamentarium: Multitarget Senotherapeutic and Regenerative Strategies. J Am Soc Nephrol. 2025 May 7;36(8):1655-1658. doi: 10.1681/ASN.0000000754. No abstract available.
- Andrews TD, Day GS, Irani SR, Kanekiyo T, Hickson LJ. Uremic Toxins, CKD, and Cognitive Dysfunction. J Am Soc Nephrol. 2025 Jun 1;36(6):1208-1226. doi: 10.1681/ASN.0000000675. Epub 2025 Feb 26.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic adipose-derived mesenchymal stem cells (MSC) | Cell therapy | 7.5e+07 cells | Intravenous |
| Subject | Allogeneic adipose-derived mesenchymal stem cells (MSC) | Cell therapy | 1.5e+08 cells | Intravenous |